Table 1.
Baseline characteristics of the study population.
| Total (N = 102) | |
|---|---|
| Age | |
| Median (range) | 58.0 (28–79) |
| Sex | |
| Male | 59 (57.8%) |
| Female | 34 (33.3%) |
| Not available | 9 (8.8%) |
| Histologic grade | |
| Well to moderately differentiated | 26 (25.5%) |
| Poorly differentiated | 66 (64.7%) |
| ICI treatment regimen | |
| Pembrolizumab | 63 (61.8%) |
| Nivolumab | 30 (29.4%) |
| Not available | 9 (8.8%) |
| PD-L1 staining (DAKO 22C3) | |
| CPS ≥ 1% | 43 (42.2%) |
| CPS < 1% | 51 (50.0%) |
| Not available | 8 (7.8%) |
| Data available for RNA-seq | 45 (44.1%) |
| Data available for pathology | 93 (91.2%) |
| Overall response | |
| CR | 3 (2.9%) |
| PR | 19 (18.6%) |
| SD | 29 (28.4%) |
| PD | 51 (50.0%) |
| Progression-free survival (months) | |
| Median (range) | 3.07 (0.47–33.03) |
| Overall survival (months) | |
| Median (range) | 6.72 (0.47–33.03) |
ICI immune checkpoint inhibitors, RNA-seq RNA sequencing, CPS combined positive score, CR complete response, PR partial response, SD stable disease, PD progressive disease.